Coloplast stock reports 6 percent organic growth in Q3
Published on 09/24/2026 at 23:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Coloplast stock stood at DKK 420.60 on Nasdaq Copenhagen on September 24, 2026, after a 0.24 percent daily gain. The latest operating update showed 6 percent organic growth in Q3 2025/26, while the medical device maker continues to face margin pressure from its Biologics business.
Q3 growth reaches 6 percent
According to Trivano, Coloplast delivered 6 percent organic growth in Q3 2025/26 and 5 percent EBIT growth in constant currencies. Reported revenue for the first nine months rose 3 percent, reflecting a 3 percentage point currency headwind.
The nine-month EBIT reached DKK 5,599 million, up 5 percent in constant currencies, while the EBIT margin was 26 percent versus 27 percent in the prior-year period. The gap between organic growth and reported revenue growth shows how exchange rates continue to dilute the operational result.
Biologics weighs on margins
The same 9M 2025/26 report said Biologics remained affected by reimbursement-related challenges, while Chronic Care and Interventional Urology delivered stronger operating trends. Adjusted diluted earnings per share before special items increased 14 percent during the nine-month period.
For investors, the margin comparison is the key signal. A 26 percent margin against 27 percent a year earlier means revenue growth is not translating fully into operating profitability, particularly as Coloplast integrates its Kerecis wound-care business.
Analyst estimates move lower
As Investing.com reported on September 9, 2026, J.P. Morgan lowered its fiscal 2027 adjusted EPS estimate to DKK 27.20 from DKK 27.58, a 1.4 percent reduction. The bank also cut its fiscal 2027 sales estimate to DKK 30.83 billion from DKK 30.958 billion.
The market valuation reflects that tension. Coloplast's market capitalization was DKK 94,761,542,557 on September 24, 2026, while the 52-week range stood at DKK 369.70 to DKK 631.40. The latest price was 33.4 percent below the 52-week high.
Stock remains below yearly high
Coloplast's closing price was DKK 420.60 on Nasdaq Copenhagen on September 24, 2026. The combination of 6 percent organic growth and a 26 percent EBIT margin leaves margin development as the central measure for the next reported period.
Coloplast stock key data
- Company: Coloplast A/S
- Ticker: COLO B
- Trading venue: Nasdaq Copenhagen
- Closing price (September 24, 2026): DKK 420.60
- Market capitalization: DKK 94,761,542,557 (as of September 24, 2026)
- 52-week range: DKK 369.70-631.40 (as of September 24, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
